Orphan Drug Production
-
Subject Areas on Research
- Aerosolized ribavirin: the most expensive drug for pneumonia.
- Assessing the economic challenges posed by orphan drugs.
- Congress, the FDA, and the fair development of new medications for children.
- Developing drugs for developing countries.
- Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.
- Ethical considerations in design of a study to evaluate a US Food and Drug Administration-approved indication: antivenom versus placebo for copperhead envenomation.
- Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention
- Innovative design and analysis for rare disease drug development.
- Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.
- Priorities for the Priority Review Voucher.
- Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
- Repairing the broken market for antibiotic innovation.
- Should the patent system for new medicines be abolished?
- Statistical considerations for rare diseases drug development.
- The Commercial Market For Priority Review Vouchers.
- The distribution of sales revenues from pharmaceutical innovation.
- The quantity and quality of worldwide new drug introductions, 1982-2003.
- The roles of patents and research and development incentives in biopharmaceutical innovation.